



Methyl Gallate from *Galla rhois* Successfully Controls Clinical Isolates of *Salmonella* Infection in Both *In Vitro* and *In Vivo* Systems

Jang-Gi Choi^{1,2}, Su-Hyun Mun³, Harendra S. Chahar², Preeti Bharaj², Ok-Hwa Kang¹, Se-Gun Kim¹, Dong-Won Shin⁴, Dong-Yeul Kwon^{1*}

1 Department of Oriental Pharmacy, College of Pharmacy, Wonkwang University, Wonkwang Oriental Medicines Research Institute, Institute of Biotechnology, Jeonbuk, Korea, **2** Center of Excellence in Infectious Disease Research, Department of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, Texas, United States of America, **3** BK21 Plus Team, Professional Graduate School of Oriental Medicine, Wonkwang University, Iksan, Jeonbuk, Republic of Korea, **4** Department of Oriental Medicine Resources, Sunchon National University, Jeonnam, Republic of Korea

Abstract

Galla rhois is a commonly used traditional medicine for the treatment of pathogenic bacteria in Korea as well as in other parts of Asia. Methyl gallate (MG), a major component of *Galla Rhois*, exhibits strong antibacterial activity, but its mechanism of action against *Salmonella spp.* is unclear. In the present study, we investigated the antibacterial actions of MG against *Salmonella*. The antibacterial activity determined by broth dilution method indicated that the antibacterial activity of MG against *Salmonella* strains ranged from 3.9 to 125 µg/ml. *In vitro* bacterial viability test indicated that MG significantly decreased the viability of *Salmonella* over 40% when combined with ATPase inhibitors. The time-kill curves showed that a combined MG and ATPase inhibitors (DCCD and NaN₃) treatment reduced the bacterial counts dramatically after 24 h. Oral administration of MG showed a strong anti-bacterial activity against WS-5 infected BALB/c mice. In contrast to the untreated *Salmonella* infected control animals, MG treated groups showed no clinical symptoms of the disease, such as lethargy and liver damage. It was observed that MG treatment significantly increased the survival of animals from *Salmonella* infection, while in untreated groups all animal succumbed to disease by the sixth day post infection. Thus, the present study demonstrates the therapeutic ability of MG against *Salmonella* infections.

Citation: Choi J-G, Mun S-H, Chahar HS, Bharaj P, Kang O-H, et al. (2014) Methyl Gallate from *Galla rhois* Successfully Controls Clinical Isolates of *Salmonella* Infection in Both *In Vitro* and *In Vivo* Systems. PLoS ONE 9(7): e102697. doi:10.1371/journal.pone.0102697

Editor: Herbert B. Tanowitz, Albert Einstein College of Medicine, United States of America

Received: February 3, 2014; **Accepted:** June 22, 2014; **Published:** July 21, 2014

Copyright: © 2014 Choi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by Wonkwang University in 2013. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: sssimi@wku.ac.kr

Introduction

Salmonella enterica is a gram-negative bacterial pathogen capable of infecting animals and humans, causing significant morbidity and mortality worldwide [1]. *Salmonella* is a clinically important intracellular bacterial pathogen that leads to food poisoning and gastroenteritis in millions of people worldwide each year [2]. It is even a problem in industrialized nations, and the Centers for Disease Control (CDC) estimate that there are nearly 1.4 million foodborne *Salmonella* infections annually in the United States [3]. *S. Typhimurium*, *S. Enteritidis* and *S. Typhi* were the most frequent *Salmonella* serovars in foodborne diseases and diarrhea patients in Korea from 1998 to 2007 [4]. Similarly, serotypes that are highly adapted to poultry include *S. Gallinarum*, resulting in high morbidity and mortality [5].

Following oral acquisition, *Salmonella* infects the intestinal tract and can disseminate to cause systemic infection of various organs including the liver [6]. One major concern to public health has been the global dissemination of *Salmonella* Typhimurium definitive Type 104, which is commonly resistant to five or more antimicrobial agents [7–10]. Recent reports of infections related to strains of *Salmonella* with high-level resistance to antibiotics are

therefore particularly worrying. The rise in antibiotic-resistant pathogens has led to the development of new therapeutic agents that are effective against these bacteria. Recently, there has been considerable interest in the use of plant materials as an alternative method to control pathogenic microorganisms [11], and many compounds of plant products have been shown to specifically target against resistant pathogenic bacteria [11].

Galla rhois is the term used for the gall caused by the Chinese sumac aphid, *Schlechtendalia chinensis* (Bell), on the nutgall sumac tree, *Rhus javanica* L. (Anacardiaceae) [12]. It has been used in traditional Korean medicine and other oriental medicine systems for years. It has long been used for the treatment of diarrhea, prolonged coughing, and spontaneous perspiration in Korea. It is a natural non-toxic traditional Korean medicine and contains several tannin-derived components, such as methyl gallate (MG) and gallic acid [12]. MG is a phytochemical compound with strong antioxidant properties found in various species including Meliaceae, *Galla Rhois*, *Rosa Rugosa* and it is also well known as an anti-oxidative beverage [13]. In addition, MG possesses other biological activities such as anti-platelet activity, protection of DNA damage against oxidative stress [14], protection of lung injury induced by phosgene [15], attenuation of diabetic oxidative

stress and anti-apoptotic activity [15]. MG is known to perform a wide spectrum of biological activities, but its mechanism for antibacterial activity against *Salmonella* remains unclear. We hypothesized that there is synergy between MG and bacterial membrane permeabilization/binding agents such as tris(hydroxymethyl)aminomethane (TRIS), triton X-100 (TX) [16–18]. MG may be responsible for its increased antibacterial activity against *Salmonella*. Second, MG may exert its inhibitory effect on the bacterial replication by inhibiting cytochrome oxidase or by inhibition of proton-driven ATPases [16–18]. As a result, we decided to investigate the *in vitro* activities of MG separately or in combination with the bacterial membrane-binding agents TRIS and TX, and the ABC transporter-inhibiting agents NaN₃ and inhibitor of proton-driven ATPases *N,N'*-Dicyclohexylcarbodiimide (DCCD). In addition, we investigated the antimicrobial activity of MG against *Salmonella in vivo*.

Materials and Methods

Plant materials

Galla Rhois, purchased from the Oriental drug store Daehak Hanyak kuk (Iksan, Korea), was authenticated by Dr. D.Y. Kwon. A voucher specimen (No. 06-021) was deposited in the Laboratory of Herbalogy, College of Pharmacy, Wonkwang University, Iksan, Korea.

Bacterial strains

Various *Salmonella* listed in Tables S1, were used in this study. We also tested the antimicrobial activity of MG against local isolates of *S. Enteritidis*, *S. Gallinarum* and *S. Typhimurium*, which were generously provided by the National Veterinary Research and Quarantine Service, Republic of Korea and kept as frozen glycerol stock. Cells in frozen stock were streaked onto nutrient agar medium to produce cell colonies, from which a single colony was transferred to Mueller-Hinton agar (MHA). For preparation of inocula, cells were grown for 20 h at 37°C in Mueller-Hinton broth (MHB). For mouse infection, cultured bacterial cells (WS-5) were recovered by centrifugation at 13,000 rpm for 30 s and then washed with and resuspended in PBS [19]. The McFarland standard turbidity of the cell suspensions was measured. The cell suspensions were diluted with PBS to the desired concentration of bacteria using a standard curve of optical density versus bacterial number determined as colony-forming units (CFU). Confirmation of *Salmonella* strains were performed by a PCR assay described by a previous report [20,21].

Reagents and instruments

NMR spectra were measured with a JEOL Eclipse 500 FT-NMR spectrometer (¹H, 500 MHz; ¹³C 125 MHz). Column chromatography was carried on silica-gel (Kieselgel 60, 70–230 mesh, Merck, Germany), a thin layer chromatography (TLC) on pre-coated Silica-gel F254 (0.25 mm, Merck) and Sephadex LH-20 (25–100 μM, Sigma, U.S.A). Mueller-Hinton broth (MHB) and Mueller-Hinton agar (MHA) (Difco Laboratories, Baltimore, MD, USA). Ampicillin, amoxicillin/clavulanic acid, chloramphenicol, cephalothin, sulfisoxazole, nalidixic acid, norfloxacin, streptomycin, trimethoprim/sulfamethoxazole, ticarcillin, ciprofloxacin, *N,N'*-Dicyclohexylcarbodiimide, Sodium azide, Tris, Triton X-100 and solvents were purchased from Sigma Aldrich (St. Louis, USA).

Isolation of methyl gallate

The EtOH extracts were partitioned with organic solvents of different polarities to yield n-Hexane, EtOAc, n-BuOH and H₂O fractions, in sequence (Figure 1). The EtOAc fraction of each plant was subjected to silica gel chromatography with CH₂Cl₂-MeOH-H₂O (lower layers, by volume, 5:1:1→7:3:1) as the solvents to yield MG from *Galla Rhois* (Figure 1). The structure of the compound (Table 1) was determined by its physico-chemical and spectral data (¹H-NMR and ¹³C-NMR) which were in agreement with those reported in literature [22,23].

Antimicrobial resistance testing

Resistance of the *Salmonella* strains to the different antimicrobial agents was determined using the disc-agar method based on interpretations according to Clinical and Laboratory Standards Institute (CLSI) [24]. The quality control strains were *Enterococcus faecalis* ATCC 29212 and *Escherichia coli* ATCC 25922 (Table S1).

Disc diffusion

The paper disc diffusion method was used to determine antibacterial activity [25]. Sterile paper discs (6 mm; Toyo Roshi Kaihsa, Japan) were loaded with 20 μl of MG (varying concentrations: 10, 50, and 100 μg) dissolved in 10% dimethyl sulfoxide (DMSO, Sigma, USA), and were left to dry for 12 h at 37°C in a sterile room. The bacterial suspensions were diluted to match the 0.5 McFarland standard scale (approximately 1.5 × 10⁸ CFU/ml), and were further diluted to obtain the final inoculum. The MHA was poured into petri dishes and inoculated with 100 μl of the suspension containing 1 × 10⁵ CFU of bacteria. The inhibition zone diameter around each of the discs was measured and recorded at the end of the incubation period. Ampicillin was included as positive control and 10% DMSO served as negative controls.

Determination of the minimum inhibitory concentrations (MICs)

The minimal inhibition concentration (MIC) values were determined for the microorganisms we found to be sensitive to MG during the disc diffusion assay. A preparation of the microorganism inocula was from 12 h broth cultures and the suspensions were adjusted to a 0.5 McFarland standard turbidity. Susceptibility tests were carried out by the standard broth micro dilution method [26] in MHB with an inoculum of approximately 5 × 10⁴ CFU/ml. The MHB was supplemented with serial MG at




Figure 1. Isolation of methyl gallate from *Galla rhois*. (A) Chemical structure of methyl gallate, (B) Procedures of extraction and fraction of the *Galla Rhois*, (C) Column chromatographic procedures of n-EtOAc fraction.

doi:10.1371/journal.pone.0102697.g001

Table 1. ^1H - and ^{13}C -NMR spectral data of compound 1 (methyl gallate) isolated from *Galla Rhois*.

Carbon NO.	^1H -NMR	^{13}C -NMR
1		119.8
2	6.93	109.1
3		146.1
4		138.9
5		146.1
6	6.93	109.1
COOCH_3		166.8
COOCH_2	3.73	52.1

Solvent: DMSO- d_6 .

doi:10.1371/journal.pone.0102697.t001

concentrations from 0.97 to 1000 $\mu\text{g}/\text{ml}$. The data were reported as MICs, the lowest concentration of MG inhibiting visible growth after 24 hours of incubation at 37°C [26]. The MICs of ampicillin was also determined, and similarly defined as the lowest antibiotic concentration at which no visible bacterial growth was observed.

Anti-bacterial activity with detergents or ATPase-inhibitors

To elucidate whether anti-bacterial activity of MG was associated with the altered membrane permeability or anti-bacterial susceptibility, effect of MG was examined in the presence of detergents or ATPase-inhibiting agents. Minimum inhibitory concentrations (MICs) of the selected antimicrobial agents (detergents or ATPase-inhibiting agents) were determined by micro broth dilution assays. To increase the permeability of the outer membrane, the concentration of MG, (a fractional inhibitory concentration (FIC) determined in a combination assay with other therapeutic agents) was added to bacterial cells in the presence of 0.001% Triton X-100, and 125 $\mu\text{g}/\text{ml}$ Tris, respectively. NaN₃ and DCCD were used as inhibitors of ATPase [16–18]. The anti-bacterial susceptibility of MG in the presence of 0.005% NaN₃ and 125 $\mu\text{g}/\text{ml}$ DCCD, was also carried out at the same condition. The viability of bacteria was determined by a spectrophotometer (optical density at 600 nm, OD₆₀₀) after incubation for 24 h. *In vitro* synergy between the agents was evaluated by time-kill assay as described previously [18]. The synergy between each pair of antimicrobial agents was determined using time-kill curves of bacterial growth in 96-well plates at five different time-points (0, 2, 4, 8 and 24 h) (12). Bacterial cultures were diluted with fresh MHB to $\sim 1.5 \times 10^5$ CFU/ml, and incubated at 37°C for 24 h. Aliquots (0.1 ml) of the culture were taken following 0, 2, 4, 8 and 24 h of incubation, and serial 10-fold dilutions were prepared in saline. For samples obtained from each time-point, the number of viable cells was determined on a drug-free MHA plate following incubation for 24 h. Colony counts were performed on plates and 30–300 colonies were counted. The lower limit of sensitivity for the colony counts was 100 CFU/ml. Antimicrobial agents were considered to be bactericidal at the lowest concentration that reduced the original inoculum by 3 log₁₀ CFU/ml (99.9%) for each of the indicated time-points [22]. Synergy was defined as ≥ 2 log₁₀ decrease in the number of CFU/ml between the combination and the most active compound [27,28]. To confirm the results, time-kill assays for each experiment were performed in triplicate. Data are presented as the mean \pm standard deviation [18].

In vivo assay using mice

Mice were obtained from Da Mool Science (Daejeon, Korea). All mice experiments in this study were approved by the Wonkwang National University Animal Ethics Committee in accordance with the guidelines of the Korean Council on Animal Care. Thirty male BALB/c mice (15–17 g) between 5 and 6 weeks old were used for all *in vivo* experiments. All animals were kept in a temperature-controlled room under a 12 h light \sim 12 h dark cycle. Animals had free access to commercial solid food (SCF Co., Ltd. Korea) and water ad libitum, and were acclimatized for at least 1 week prior to beginning the experiments. Mice were divided into the following groups: *Salmonella*-infected (SI), and *Salmonella*-infected + MG (SIMG). For survival and fecal shedding each treatment group contained 10 mice in SI and SIMG group. Each mouse was caged individually and subjected to infection as described below. For histopathologic examinations, a separate set of 5 mice per group (SI and SIMG) were infected and sacrificed consecutively for 3 days post infection. Tissue specimens of the liver were transferred into 10% buffered neutral formalin for histopathologic examinations and then processed using standard procedures. Sections of paraffin-embedded tissues were then stained with hematoxylin and eosin. Throughout each experiment, mice were provided with water that contained streptomycin (5 mg/ml) to reduce the level of facultative anaerobic bacteria that normally colonize the mouse intestine [28–30]. *S. Typhimurium* (WS-5) was grown overnight in Luria–Bertani broth (Difco), centrifuged, washed in phosphate-buffered saline (PBS), and then diluted to achieve a final concentration of 1×10^4 CFU. Mice were orally infected with *S. Typhimurium* (1×10^4 CFU) using a gavage needle; the suspensions were then diluted in 20% sucrose and fed to the SI and SIMG groups. One hour after infection, animals in the SIMG group were orally administered 50 mg/kg of the MG daily by gavage needle as described before [28], SI group treated with sterile PBS and administered to the animals in similar manner. Fecal samples were collected at 0, 1, 3, 4 and 5 days after administering the bacterial suspensions and the numbers of the bacteria per gram in feces were determined. Aliquots (100 μl) of fecal suspensions were serially diluted in PBS and then were plated on duplicate *Salmonella*–Shigella agar plates (Difco), which were then incubated overnight at 37°C , and typical colonies were counted for plates containing between 30 and 300 colonies. Confirmation of *S. Typhimurium* was performed by a PCR assay described by a previous report [20,21].

Statistical analysis

The data were analyzed using Graph-Pad Prism software 5 (GraphPad Software, Inc., San Diego, CA) or Microsoft Excel. Results are given as means with standard deviation. Comparisons were made using the Pearson two-tailed test. All data with $P < 0.05$ were considered significant.

Results

Anti-bacterial activity of MG against *Salmonella*

The antimicrobial efficacy of MG against the ten *Salmonella* strains was evaluated by the disc diffusion method via determination of the surrounding inhibition zones, as well as by evaluating the MIC using the broth micro dilution method. Table 2 shows the antimicrobial activity of MG determined by the disc diffusion method. The values of the inhibition zones produced against the tested bacteria ranged between 12 and 26 mm. The growth of all the tested strains was inhibited at 100 μg per disc. In addition, the response was dose-dependent, meaning the higher the dose the wider the inhibition zone. The MICs for MG and ampicillin against the 10 strains of *Salmonella* are shown in Table 3. The MICs determined using the broth dilution method confirmed the antimicrobial effects found through the disc diffusion method. MG showed antimicrobial activity against all the tested strains. The MICs of MG against the 10 *Salmonella* strains ranged from 3.9 to 125 $\mu\text{g}/\text{ml}$, and for ampicillin from 0.09 to 1000 $\mu\text{g}/\text{ml}$.

Anti-bacterial activity with detergents or ATPase-inhibitors

To investigate the effects of enhanced membrane permeability on the activity of MG using detergents, the anti-bacterial activity of MG under increased membrane permeability was examined using 125 $\mu\text{g}/\text{ml}$ Tris, and 0.001% Triton X-100. Tris and Triton X-100 all of which are membrane-permeabilizing agents (all reagents used 1/2 MIC) that can increase the permeability of the outer membrane in Gram negative bacteria by binding lipopolysaccharide (LPS) [31,32]. These agents did not have any enhancing effect on the antibacterial activity of MG (Figure S1). We investigated bacterial viability in the presence of MG with 0.005% NaN₃ and 125 $\mu\text{g}/\text{ml}$ DCCD (all reagents used 1/2 MIC) as a metabolic inhibitor which can decrease ATP levels by disrupting electrochemical proton gradients in a bacterial envi-

ronment [33,34]. MG in combination with NaN₃ and DCCD significantly decreased the viability of WS-5 over 40% (Figure S1). Time-kill assays were performed for MG in combination with ATPase inhibitors (NaN₃ and DCCD) for two strains *S. Typhimurium* (WS-5) and *S. Typhi* ATCC 19943 (WS-7) strains. Figure 2A and B shows that MG and DCCD alone at 1/2 MIC had very weak effect against both stationary-phase WS-5 and WS-7. NaN₃ alone at 1/2 MIC reduced the CFU counts 3~5 log of bacteria 24 h of incubation. However, the combination of MG and DCCD or NaN₃ reduced the CFU counts to zero at 24 h of incubation for WS-7 and also MG and DCCD or NaN₃ reduced CFU counts 2~4 log the period of 24 h of incubation for WS-5. The time-kill assay demonstrated that there was a significant synergistic activity between MG and NaN₃ or DCCD for the *Salmonella* strains tested (Figure 2).

In vivo assay using mice

Barthel *et al.* [30] described a versatile animal model to understand the molecular mechanisms of enteric salmonellosis. We employed a similar *in vivo* model in the present study to determine the protective effects of MG against *S. Typhimurium* (WS-5) infection in mice. Briefly, mice were infected with 1×10^4 CFU of *S. Typhimurium* (SI). One hour later, the mice were orally administered MG (50 mg/kg). As shown in Figure 3A, treatment with the MG was found to have marked effects on mortality and in the MG treated group 70% of the animals survived while all animals in the untreated group infected with *Salmonella* died by the sixth day post infection. MG was found to have marked effects on the numbers of viable *S. Typhimurium* recovered from feces. At day 3 post-infection, seven of ten mice in the test group did not shed viable *S. Typhimurium* in feces, whereas all mice (1 mouse died) in the control group shed bacteria ranging $1.7 \times 10^3 \sim 1.2 \times 10^5$ CFU/g in feces (Figure 3B). *S. Typhimurium*-infected mice that did not receive the MG were lethargic and showed signs of histological damage in the liver. In addition, the central and portal veins of the liver showed congestion with focal necrotic emboli-like materials (Figure 3C). Five different sections from liver of each mice were tested for necrotic lesions and neutrophil expression. There were multiple small necrotizing nodular lesions in the liver parenchyma with inflammatory cell infiltrate. Conversely, clinical signs and histo-

Table 2. Antimicrobial activity (as the inhibition zone diameter) of methyl gallate (MG) and ampicillin against *Salmonella*.

Strains	Serotypes	Origin	MG			^a Ampicillin
			10 μg	50 μg	100 μg	10 μg
WS- 1	<i>S. Gallinarum</i> ATCC 9184	Chicken	[*] ND	11	20	ND
WS- 2	<i>S. Gallinarum</i>	Chicken	ND	ND	15	ND
WS- 3	<i>S. Gallinarum</i>	Chicken	ND	ND	14	27
WS- 4	<i>S. Typhimurium</i>	Cattle	ND	ND	12	30
WS- 5	<i>S. Typhimurium</i>	Pig	ND	7	12	ND
WS- 6	<i>S. Enteritidis</i>	Human	7	18	25	27
WS- 7	<i>S. Typhi</i> ATCC 19943	Human	8	15	23	30
WS- 8	<i>S. Paratyphi</i> A	Chicken	7	14	26	28
WS- 9	<i>S. Enteritidis</i>	Chicken	ND	13	20	33
WS- 10	<i>S. Enteritidis</i>	Chicken	ND	10	13	31

^{*}ND, No activity detected, ^a Positive control.
doi:10.1371/journal.pone.0102697.t002

Table 3. Antimicrobial activity of MG and ampicillin against 10 strains of *Salmonella*.

Strains	Serotypes	Origin	^a MIC (ug/ml)	
			MG	^b Ampicillin
WS- 1	<i>S. Gallinarum</i> ATCC 9184	Chicken	31.25	1000
WS- 2	<i>S. Gallinarum</i>	Chicken	3.9	1000
WS- 3	<i>S. Gallinarum</i>	Chicken	15.6	0.97
WS- 4	<i>S. Typhimurium</i>	Cattle	3.9	0.97
WS- 5	<i>S. Typhimurium</i>	Pig	15.6	1000
WS- 6	<i>S. Enteritidis</i>	Human	3.9	1.95
WS- 7	<i>S. Typhi</i> ATCC 19943	Human	3.9	0.97
WS- 8	<i>S. Paratyphi</i> A	Chicken	31.25	0.97
WS- 9	<i>S. Enteritidis</i>	Chicken	125	0.97
WS- 10	<i>S. Enteritidis</i>	Chicken	31.25	1.95

^aMIC, Minimum inhibitory concentration. ^b Positive control.
doi:10.1371/journal.pone.0102697.t003

logical damage were rarely observed in *S. Typhimurium*-infected mice fed with MG.

Discussion

Due to the recent appearance of the “Super Bacteria” of *Salmonella* DT 104 showing resistance to multiple antibiotics and the intractable bacterial types of *Escherichia coli* (E. coli O157, O111, O26) releasing stronger toxin due to the application of antibiotics, the development of new antibiotics is urgently required, which is even tendered as a social issue [35,36]. To overcome the emerging problem of bacterial antibiotic resistance, studies investigating plant extracts with antibiotics against clinical strains have been reported [7–9].

Galla Rhois is naturally found in Korea and China, where it is known as Chinese Sumac and has been used in the treatment of cold, fever, cough and malaria. It was previously reported that the methanol extract of *Galla Rhois* had significant growth-inhibitory activity towards both *Clostridium perfringens* and *Escherichia coli* [12]. MG is the main component of *Galla Rhois*, displaying several biological activities, and presents activity against *Salmonella*. It is observed that the anti-bacterial activity of MG described in this study is in agreement with results reported by others, showing that the activity of *Galla Rhois*, and of other species against *Salmonella*, is due to this compound [37,38]. The

potential of MG to enhance the activity of antibiotics against *Salmonella* was studied previously [37,38] but the function of MG in *Salmonella* is still unclear. Therefore we investigated for the mechanism of MG against *Salmonella*. Antibacterial agents such as β -lactams antibiotics are inhibitor of cell wall synthesis [39], and fluoroquinolone antibiotics are inhibitor of DNA gyrase against both Gram-positive and Gram-negative bacteria [40]. In this study, MG was used in combination with detergents (TX and Tris) responsible for increasing the membrane permeability of bacterial strain. However, additional decrease in bacterial replication was not observed as determined by the OD value, where the bacterial culture was treated with MG along with cell of membrane-permeabilizing agents. Which indicates that may be MG does not interfere with cell wall synthesis. In contrast, MG in combination with ATPase inhibitors (NaN₃ and DCCD) significantly decreased the viability of *Salmonella* WS-5 as determined by spectrophotometry. As determined in time-kill studies, MG in combination with ATPase inhibitors shows synergistic effect against WS-5 and WS-7.

This finding indicates that the primary mechanism of MG action is via DNA gyrase or ATPase inhibition in the *Salmonella* but not via cell wall synthesis inhibition. In our previous study, we found that the combination of MG, at sub-MIC concentrations, with ciprofloxacin and nalidixic acid significantly improved the




Figure 2. Time-kill curves for (A) *S. Typhimurium* (WS-5) and (B) *S. Typhi* ATCC 19943 (WS-7) with MG and ATPase inhibitors (DCCD and NaN₃). These results were confirmed in three independent experiments.
doi:10.1371/journal.pone.0102697.g002




Figure 3. Therapeutic effects of MG treatment on mice infected with *Salmonella*. (A) the survival of mice (n = 10, per group) treated or untreated with MG, infected with WS- 5, (B) Effects of feeding MG on fecal shedding of *S. Typhimurium* (CFU/g) from mice. (C) Histopathological changes in liver of *Salmonella*-infected and *Salmonella*-infected treated MG. *Salmonella*-infected (SI) and *Salmonella*-infected + MG (SIMG). All data with P<0.05 were considered significant.
doi:10.1371/journal.pone.0102697.g003

activity of the antibiotic [37,38]. MG and fluoroquinolone antibiotics (ciprofloxacin and nalidixic acid) directly or indirectly attack the same target: DNA gyrase or ATPase inhibition in the *Salmonella* [39,41]. The additive or neutral effects of MG in combination with other agents strongly support this explanation. In the *in vivo* experiments using mice, the test group dosed with 50 mg/kg of MG, showed clear MG mediated protection which resulted in survival of 70% of mice during 6 days of experiment. However, all the mice in SI group died by 6 day of the experiment. In addition, the cytological identification of liver in MG dosed mice revealed less expression of neutrophil in SIMG group as compared to SI group by showing the treatment effect of MG against murine salmonellosis.

Hence the findings of our study clearly demonstrate the usefulness of MG in treatment of *Salmonella* infections and may provide the preliminary supportive data for in-depth studies regarding the mechanism of action of MG against bacterial pathogens. Therefore, it is possible to conclude that MG has the potential for use in the treatment of *Salmonella* infections in mice.

References

- Fink SL, Cookson BT (2007) Pyroptosis and host cell death responses during *Salmonella* infection. *Cell Microbiol* 9: 2562–2570.
- Grassl GA, Valdez Y, Bergstrom KS, Vallance BA, Finlay BB (2008) Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis. *Gastroenterology* 134: 768–780.
- Mead PS, Slutsker L, Dietz V, McCaig LF, Bresee JS, et al. (1999) Food-related illness and death in the United States. *Emerg Infect Dis* 5: 607–625.
- Kim S (2010) *Salmonella* serovars from foodborne and waterborne diseases in Korea, 1998–2007: total isolates decreasing versus rare serovars emerging. *J Korean Med Sci* 25: 1693–1699.
- Barrow PA, Freitas Neto OC (2011) Pullorum disease and fowl typhoid—new thoughts on old diseases: a review. *Avian Pathol* 40: 1–13.
- Coburn B, Grassl GA, Finlay BB (2007) *Salmonella*, the host and disease: a brief review. *Immunol Cell Biol* 85: 112–118.
- Gebreyes WA, Thakur S, Davies PR, Funk JA, Altier C (2004) Trends in antimicrobial resistance, phage types and integrons among *Salmonella* serotypes from pigs, 1997–2000. *J Antimicrob Chemother* 53: 997–1003.
- Perron GG, Bell G, Quessy S (2008) Parallel evolution of multidrug-resistance in *Salmonella enterica* isolated from swine. *FEMS Microbiol Lett* 281: 17–22.
- Poppe C, Ziebell K, Martin L, Allen K (2002) Diversity in antimicrobial resistance and other characteristics among *Salmonella typhimurium* DT104 isolates. *Microb Drug Resist* 8: 107–122.
- Threlfall EJ, Ward LR, Frost JA, Willshaw GA (2000) Spread of resistance from food animals to man—the UK experience. *Acta Vet Scand Suppl* 93: 63–68; discussion 68–74.
- Aqil F, Khan MS, Owais M, Ahmad I (2005) Effect of certain bioactive plant extracts on clinical isolates of beta-lactamase producing methicillin resistant *Staphylococcus aureus*. *J Basic Microbiol* 45: 106–114.
- Ahn YJ, Lee CO, Kwon JH, Ahn JW, Park JH (1998) Growth-inhibitory effects of *Galla Rhois*-derived tannins on intestinal bacteria. *J Appl Microbiol* 84: 439–443.
- Chen A, Zhang L (2003) The antioxidant (-)-epigallocatechin-3-gallate inhibits rat hepatic stellate cell proliferation *in vitro* by blocking the tyrosine phosphorylation and reducing the gene expression of platelet-derived growth factor-beta receptor. *J Biol Chem* 278: 23381–23389.
- Hsieh TJ, Liu TZ, Chia YC, Chern CL, Lu FJ, et al. (2004) Protective effect of methyl gallate from *Toona sinensis* (Meliaceae) against hydrogen peroxide-induced oxidative stress and DNA damage in MDCK cells. *Food Chem Toxicol* 42: 843–850.
- Sciuto AM, Moran TS (2001) Effect of dietary treatment with n-propyl gallate or vitamin E on the survival of mice exposed to phosgene. *J Appl Toxicol* 21: 33–39.
- Linnett PE, Beechey RB (1979) Inhibitors of the ATP synthetase system. *Methods Enzymol* 55: 472–518.
- Jung HJ, Lee DG (2008) Synergistic antibacterial effect between silybin and N,N'-dicyclohexylcarbodiimide in clinical *Pseudomonas aeruginosa* isolates. *J Microbiol* 46: 462–467.
- Mun SH, Joung DK, Kim SB, Park SJ, Seo YS, et al. (2014) The mechanism of antimicrobial activity of sophoraflavanone B against methicillin-resistant *Staphylococcus aureus*. *Foodborne Pathog Dis* 11: 234–239.
- Kim SP, Park SO, Lee SJ, Nam SH, Friedman M (2014) A Polysaccharide isolated from the liquid culture of *Lentinus edodes* (Shiitake) mushroom mycelia containing black rice bran protects mice against salmonellosis through upregulation of the Th1 immune reaction. *J Agric Food Chem* 62: 2384–2391.

Supporting Information

Figure S1 The effects of membrane-permeabilizing agent and ATPase-inhibitor agent on *Salmonella* (WS-5) susceptibility to MG. The viability of bacteria was determined by a spectrophotometer (optical density at 600 nm, OD₆₀₀) after incubation for 24 h with 1/2 MIC MG and the indicated concentration of Tris, TX, NaN₃ and DCCD in WS-5 (the data are Mean ± S.D. for triple-independent experiments. A(Tris), B (TX), C(NaN₃), D(DCCD). (TIF)

Table S1 List of *Salmonella* strains used in this study and growth inhibition zones produced by antibiotics. (DOCX)

Author Contributions

Conceived and designed the experiments: JC DK. Performed the experiments: JC SM OK SK DK. Analyzed the data: JC HC PB DS DK. Contributed reagents/materials/analysis tools: JC DK. Wrote the paper: JC DK.

- Alvarez J, Sota M, Vivanco AB, Perales I, Cisterna R, et al. (2004) Development of a multiplex PCR technique for detection and epidemiological typing of salmonella in human clinical samples. *J Clin Microbiol* 42: 1734–1738.
- Trkov M, Avgustin G (2003) An improved 16S rRNA based PCR method for the specific detection of *Salmonella enterica*. *Int J Food Microbiol* 80: 67–75.
- Pourmaras S, Vrioni G, Neou E, Dendrinis J, Dimitroulia E, et al. (2011) Activity of tigecycline alone and in combination with colistin and meropenem against *Klebsiella pneumoniae* carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. *Int J Antimicrob Agents* 37: 244–247.
- Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ (2009) *In vitro* activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 53: 2360–2366.
- Clinical Laboratory Standards Institute (2012) Performance standards for antimicrobial susceptibility testing: twenty-second Informational Supplement. M100–S22. CLSI, Wayne, PA.
- Ali NA, Julich WD, Kussnick C, Lindequist U (2001) Screening of Yemeni medicinal plants for antibacterial and cytotoxic activities. *J Ethnopharmacol* 74: 173–179.
- Jones RN, Castanheira M, Rhomberg PR, Woosley LN, Pfaller MA (2010) Performance of fusidic acid (CEM-102) susceptibility testing reagents: broth microdilution, disk diffusion, and Etest methods as applied to *Staphylococcus aureus*. *J Clin Microbiol* 48: 972–976.
- Belley A, Neesham-Grenon E, Arhin FF, McKay GA, Parr TR Jr, et al. (2008) Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against *Staphylococcus aureus*. *Antimicrob Agents Chemother* 52: 3820–3822.
- Lee MH, Kwon HA, Kwon DY, Park H, Sohn DH, et al. (2006) Antibacterial activity of medicinal herb extracts against *Salmonella*. *Int J Food Microbiol* 111: 270–275.
- Myhal ML, Laux DC, Cohen PS (1982) Relative colonizing abilities of human fecal and K 12 strains of *Escherichia coli* in the large intestines of streptomycin-treated mice. *Eur J Clin Microbiol* 1: 186–192.
- Barthel M, Hapfelmeier S, Quintanilla-Martinez L, Kremer M, Rohde M, et al. (2003) Pretreatment of mice with streptomycin provides a *Salmonella enterica* serovar Typhimurium colitis model that allows analysis of both pathogen and host. *Infect Immun* 71: 2839–2858.
- Leive L (1965) Actinomycin Sensitivity in *Escherichia Coli* Produced by Edta. *Biochem Biophys Res Commun* 18: 13–17.
- Irvin RT, MacAlister TJ, Costerton JW (1981) Tris(hydroxymethyl)amino-methane buffer modification of *Escherichia coli* outer membrane permeability. *J Bacteriol* 145: 1397–1403.
- Swallow CJ, Grinstein S, Rotstein OD (1990) A vacuolar type H(+)-ATPase regulates cytoplasmic pH in murine macrophages. *J Biol Chem* 265: 7645–7654.
- Goncalves PP, Meireles SM, Neves P, Vale MG (1999) Synaptic vesicle Ca²⁺/H⁺ antiport: dependence on the proton electrochemical gradient. *Brain Res Mol Brain Res* 71: 178–184.
- Threlfall EJ (2002) Antimicrobial drug resistance in *Salmonella*: problems and perspectives in food- and water-borne infections. *FEMS Microbiol Rev* 26: 141–148.
- Meakins S, Fisher IS, Berghold C, Gerner-Smidt P, Tschape H, et al. (2008) Antimicrobial drug resistance in human nontyphoidal *Salmonella* isolates in

- Europe 2000–2004: a report from the Enter-net International Surveillance Network. *Microb Drug Resist* 14: 31–35.
37. Choi JG, Kang OH, Lee YS, Oh YC, Chae HS, et al. (2009) Antibacterial activity of methyl gallate isolated from *Galla Rhois* or carvacrol combined with nalidixic acid against nalidixic acid resistant bacteria. *Molecules* 14: 1773–1780.
 38. Choi JG, Kang OH, Lee YS, Oh YC, Chae HS, et al. (2008) In vitro activity of methyl gallate isolated from *Galla rhois* alone and in combination with ciprofloxacin against clinical isolates of salmonella. *J Microbiol Biotechnol* 18: 1848–1852.
 39. Perez-Capilla T, Baquero MR, Gomez-Gomez JM, Ionel A, Martin S, et al. (2005) SOS-independent induction of *dinB* transcription by beta-lactam-mediated inhibition of cell wall synthesis in *Escherichia coli*. *J Bacteriol* 187: 1515–1518.
 40. Falconer SB, Czarny TL, Brown ED (2011) Antibiotics as probes of biological complexity. *Nat Chem Biol* 7: 415–423.
 41. Mascellino MT, Farinelli S, Iegri F, Iona E, De Simone C (1998) Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates. *Drugs Exp Clin Res* 24: 139–151.